Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€11.31

€11.31

-2.300%
-0.268
-2.300%
€21.04

€21.04

 
18.09.24 / Tradegate WKN: A2PKMZ / Symbol: NVAX / Name: Novavax / Stock / Biotechnology & Medical Research / Small Cap /
Latest predictions
€21.04
12.08.24
6.32%
buy
€8.23
12.08.24
3.40%
€22.91
02.08.24
2.97%
buy
€26.76
23.05.24
-18.81%
buy
€17.59
13.05.24
34.44%
buy
13.05.24
37.39%
buy
Best running prediction
-
13.05.24
37.39%
buy
Your prediction

Novavax Inc. Stock

A loss of -2.300% shows a downward development for Novavax Inc..
Our community is currently high on Novavax Inc. with 5 Buy predictions and 1 Sell predictions.
With a target price of 21 € there is a hugely positive potential of 85.74% for Novavax Inc. compared to the current price of 11.31 €.
Our community identified positive and negative aspects for Novavax Inc. stock for the coming years. 10 users see the criterium "Worthwhile Investment for the next years" as a plus for the Novavax Inc. stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.

Pros and Cons of Novavax Inc. in the next few years

Pros
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Novavax Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Novavax Inc. -2.300% 1.399% -3.795% 63.146% 153.214% -94.410% 85.192%
Evolus Inc -3.360% 5.109% 20.000% 68.421% 59.116% 114.925% -
Ardelyx Inc. -3.940% -1.625% 0.453% 36.215% -7.855% 371.327% 20.280%
Coherus Bioscien. 1.760% -20.402% -16.557% -77.568% -68.750% -93.667% -95.188%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-30

General Impression

The financials of Novavax, a Biotechnology & Medical Research company with US symbol NVAX, paint a mixed picture. Over the past few years, the company has reported a significant increase in its revenue and total assets. However, its net income has consistently been in the negative, and it has faced challenges in maintaining a positive net working capital and managing its liabilities.

Detailed Analysis

Comments

Prediction Buy
Perf. (%) 6.32%
Target price 21.040
Change
Ends at 12.08.25

Novavax, Inc. (NASDAQ: NVAX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $23.00 price target on the stock, down previously from $25.00.
Ratings data for NVAX provided by MarketBeat
Show more

Prediction Sell
Perf. (%) 3.40%
Target price 8.227
Change
Ends at 12.08.25

Novavax, Inc. (NASDAQ: NVAX) had its price target raised by analysts at JPMorgan Chase & Co. from $8.00 to $9.00. They now have an "underweight" rating on the stock.
Ratings data for NVAX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 2.97%
Target price 22.910
Change
Ends at 02.08.25

Novavax, Inc. (NASDAQ: NVAX) had its price target lowered by analysts at B. Riley from $29.00 to $25.00. They now have a "buy" rating on the stock.
Ratings data for NVAX provided by MarketBeat
Show more

News

Should You Buy Novavax Stock After This Regulatory Win?: https://g.foolcdn.com/editorial/images/790012/nurse-vaccinating-elderly-patient.jpg
Should You Buy Novavax Stock After This Regulatory Win?

Vaccine maker Novavax (NASDAQ: NVAX) is having a good year. In May, the company announced a lucrative partnership with French biotech giant Sanofi (NASDAQ: SNY), sending its stock price soaring

Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?: https://g.foolcdn.com/editorial/images/789236/a-person-receiving-a-vaccine-from-a-nurse.jpg
Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?

Struggling biotech Novavax (NASDAQ: NVAX) was a hot buy a few years ago as it was in the midst of developing a vaccine for COVID-19. Ultimately, it did produce an approved vaccine, but it was a bit

Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?: https://g.foolcdn.com/editorial/images/787917/doctor-vaccinating-a-patient.jpg
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?

It's been a great year for Novavax (NASDAQ: NVAX). The biotech is up by 150% since January. However, analysts see even more upside for the vaccine maker. The consensus estimate of $20 a share